







an Open Access Journal by MDPI

Molecular Diagnosis of Interstitial Lung Disease

Guest Editor:

Dr. Ilaria Campo

UOC Pneumologia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

Deadline for manuscript submissions:

closed (29 February 2024)

Message from the Guest Editor

We are pleased to invite you to submit a paper to this Special Issue of Diagnostics entitled Molecular Diagnosis of Interstitial Lung Disease.

Interstitial lung disease (ILD) includes a group of diffuse parenchymal lung diseases that often share overlapping features. The diagnosis of ILD requires a combination of clinical data, radiological imaging, and histological findings. However, diagnoses are often delayed or misrecognized. Precise diagnosis is essential for prognostication and successful management.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

IPF; Sarcoidosis; Pulmonary alveolar proteinosis and disorders of pulmonary surfactant homeostasis; Rare interstitial pneumonia; ILD development during the course of systemic sclerosis (SSc); Multidisciplinary approaches to ILD; Potential role of artificial intelligence (AI) in ILD diagnosis; Diagnosis of post-COVID-19 ILD manifestations; Circulating biomarkers; Genetic markers for susceptibility and prognosis.

I look forward to receiving your contributions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.7 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2023).

Contact Us